Medical Dialogues

Bristol Myers Squibb BMS 986446 gets USFDA fast track designation for Alzheimer's Disease

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease ...
pharmaphorum

BMS adds discounted psoriasis drug to its DTC channel

All of the DTC channels offer discounts for people willing and able to pay for medicines with cash, and that also applies to ...
pharmaphorum

BMS says it will set Cobenfy's UK price the same as the US

The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it ...
The Pharma Letter

BMS Phase III success with iberdomide

US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...
The Pharma Letter

BMS builds on Eliquis and Sotyktu direct-to-patient program

US pharma major Bristol Myers Squibb has announced an expansion of its direct-to-patient offerings, providing eligible US ...

Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's

Bristol Myers Squibb has won Food and Drug Administration fast-track designation for its BMS-986446 drug candidate in Alzheimer's disease. Bristol Myers on Wednesday said BMS-986446 is a potential ...